IndustryCompany release

DataMEDS AI amends non-binding LOI for drone-delivery, biometric and telehealth assets and Tollo Health stake

🇺🇸 DataMeds AI, Inc. (MEDS) · Mon 26 Oct 2026

Nasdaq-listed DataMEDS AI has signed a revised letter of intent with five counterparties, targeting a Q4 2026 close, though the deal remains subject to definitive agreements and several approvals.

DataMEDS AI (NASDAQ: MEDS) announced on 22 October 2026 that it has signed an amended non-binding letter of intent, dated 19 October. The counterparties are Datavault AI, Scilex, EOS Technology, Data Health Partners and HealthBridge Advisors.

If completed, the transaction would bring into DataMEDS AI patents covering biometric confirmation of home and drone delivery of medicines, as well as technology for tracking goals related to GLP-1 therapies. It would also give the company control of Tollo Health. The company is aiming to close in the fourth quarter of 2026.

DataMEDS AI links the plan to recent FDA guidance on prescription drug apps and software. The summary of the announcement does not detail what that guidance requires or how the acquired assets would be used in practice.

The letter of intent is not binding. The deal still requires definitive agreements, due diligence, a fairness opinion and a Nasdaq change-of-control review. Financial terms were not available in the material reviewed.

What it means for your team

  • The deal is at an early, non-binding stage, so teams should treat any resulting product or service plans as provisional until definitive agreements are signed.
  • Biometric confirmation of home and drone drug delivery, if commercialised, could raise questions on chain-of-custody, patient identity verification and distribution controls that quality teams may want to monitor.
  • GLP-1 goal-tracking technology and software linked to prescription drugs are areas where regulatory teams may track how the cited FDA guidance on prescription drug apps and software is applied.
  • Completion depends on due diligence, a fairness opinion and Nasdaq review, so the Q4 2026 target may shift.

Company's press release (SEC filing): DataMeds AI, Inc. ↗

Article written by VigiEye from the official source (DataMeds AI, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →